Breast Cancer
Breast cancer starts in the cells of the breast tissues, mostly in the ducts and lobules. It is the most common cancer among Canadian women. Although rare, breast cancer also occurs in men.
It has been estimated that for the year 2011, 23,600 women would be diagnosed with breast cancer and that 5,300 would die from the disease. For that same year, an estimated 190 men would also be diagnosed with breast cancer and 55 would die from it.
One in nine women is expected to develop breast cancer during her lifetime. Based on recent statistics, one in 29 women will die of it.
Breast cancer death rates have declined in all ages combined and in every age group since at least the mid 1990s. Incidence and death rates for breast cancer have declined since 1969 in women aged 20-39. This decline has been accelerating since 2002. This can be imputed both to a more frequent use of mammography screening and to the higher effectiveness of post-operative adjuvant therapy. Indeed, the current mortality rate from breast cancer has never been as low since 1980.
Types of breast cancer
Causes – Risk factors
Signs and symptoms
Diagnosis
Treatments
Prognosis
Research projects focused on this topic
- The role of ubiquitination in the regulation of BRCA1 tumour suppressor function
- Akt isoforms in IGF-IR-induced mammary tumour growth and progression
- Role of the tumour suppressor PTEN (Phosphatase and Tensin homolog deleted on chromosome Ten) in ErbB-2 induced mammary tumorigenesis
- Role of nodal in breast cancer metastasis
- Deletion analysis of BRCA1 and BRCA2 loci in high risk breast and/or ovarian cancer families of French Canadian descent
- Mechanisms for the oncogenic effects of breast cancer susceptibility oncogene, RHAMM/HMMR.
- Regulation of ribosome biogenesis in cancer cells
- Characterization of estrogen-mediated repression of dioxin receptor signaling
- The good oncogene: eEF1A2 and the control of breast cancer outcome
- Rational Design of Novel Molecular-Targeted Inhibitors of Cancer Cell Proliferation
- Role of Akt family signaling in ErbB2 mammary tumour progression
- Autocrine motility factor as a targeted delivery agent for breast cancer treatment
- The role of Periostin/OSF-2 in ErbB2-driven tumorigenesis
- The role of Ku protein in breast tumorigenesis: implications for therapy
- Targeting RAD51/PALB2/BRCA2 homologous recombination proteins as an anti-cancer approach
- Identification of protein partners required for YB-1 to confer chemoresistance in breast tumors
- Tumour-induced osteoclast resistance to bisphosphonate action
- Biological impact of the loss of Hoxa5 function in mammary gland development and tumorigenesis
- A small molecule approach to rewiring Erb2 signalling in breast cancer
- Role of histone H3K27 demethylase JMJD3 in estrogen-dependant transcription and breast cancer
- Models for the identification of novel molecular targets and therapeutics for organ specific metastasis of breast cancer
- The contribution of specific protein arginine methyltransferases and their substrates to breast cancer tumorigenesis
- The role of the retinoblastoma protein in TGF-beta induced growth arrest
- A novel ubiquitin signaling pathway in the regulation of BRCA1 (Breast Cancer 1, early onset) tumor suppressor function
- The Role of PRMT1 Alternatively Spliced Isoform v2 in Breast Cancer Pathogenesis
- Identification and characterization of agents that enhance sensitivity to chemotherapy
- Identification of molecules that will inhibit chemoresistance conferred by YB-1 in breast tumors
- Mechanisms of action of full antiestrogens in breast cancer cells
- Molecular Characterization of the Pseudopodia of Metastatic Tumor Cells
- Regulation and Function of the RSK Family in Breast Cancer
- Defining Mechanisms by which CCN3 Promotes the Formation of Osteolytic Bone Metastases
- Role of retinoic acid synthesis in mammary gland development and tumorigenesis
- Notch4 as potential target in breast cancer stem cells
- Molecular Characterization of the Role of CSB in Tumorigenesis
- CD73-mediated chemoresistance in triple negative breast cancer
- The role of TGF-beta signalling in epigenetic stability
- A multimodal genomic analysis strategy to identify novel breast cancer genes
- Link between osteolysis and pain during breast cancer metastases to bone









